IDH1 mutations in gliomas: when an enzyme loses its grip

Abstract

The growing interest in cancer metabolism is best demonstrated by the rapid progress made in studying isocitrate dehydrogenase (IDH) mutations since their discovery just over a year ago. In a recent study published in Nature, Dang et al. identified 2-hydroxyglutarate as a product of tumor-associated IDH mutants with potential oncogenic activities.